Clinical Trials · NCT00616551

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Name: Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ambrilia Biopharma, Inc.
Enrollment: 65
Start date: Apr 2007
Locations: 6 sites, 6 countries
Primary endpoint: Compare the mean serum concentrations of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in patients treated with C2L-OCT-01 PR, 30 mg or Sandostatin LAR 30 mg

View Octreotide compound reference